DigitalDx Ventures

🚨 Portfolio Milestone Alert 🚨 DigitalDx Ventures proudly congratulates our portfolio company Biotia on a major achievement: the American Medical Association (AMA) has granted a CPT® Proprietary Laboratory Analyses (PLA) code for the BIOTIA-ID Urine NGS Assay—a major step forward in expanding access to precision diagnostics. 🔬 This newly issued code (0590U), effective October 1, 2025, marks a pivotal milestone toward broader insurance reimbursement and clinical adoption of Biotia’s genomics-based, AI-powered assay. Already approved in all 50 states—including New York—the BIOTIA-ID Urine NGS Assay offers a comprehensive, cutting-edge alternative for diagnosing recurrent and complicated UTIs where traditional methods often fall short. At DigitalDx Ventures, we invest in transformative companies digitizing the body to detect disease earlier and more accurately. Biotia is doing just that—using next-gen sequencing and microbial genomics to bring precision to infectious disease diagnostics. 👏 Congratulations to Dr. Niamh B. O'Hara, Christopher Mason, Dorottya Nagy-Szakal MD PhD, and the entire Biotia team on this important advancement for patients and providers alike! PRESS RELEASE: http://www.biotia.io/ #Biotia #DigitalDxVentures #PrecisionDiagnostics #Genomics #HealthcareInnovation #UTI #InfectiousDiseases #NGS #HealthTech #VentureCapital

Proud moment for DigitalDx Ventures! Our associate, Malika-Naomi D., had the honor of moderating a powerhouse panel of experts at the 2025 Silicon Valley Cancer Technology Conference, held on July 17th at the STANFORD FACULTY CLUB. This impactful event brought together leaders in oncology, venture capital, and health tech to explore the cutting edge of cancer care — from early detection to advanced therapeutics. The DigitalDx Ventures team was in full force at the event with Founder + Managing Partner Michele Colucci, Esq. and EIR Molly Martell in attendance as well. 🎤 Cancer Tech Investor Panelists included: Angela Jimenez MD MPS – Physician Leader, Leon Precision Capital Lu Zhang – Founder & Managing Partner, Fusion Fund Soyoung Park – General Partner, 1004 Venture Partners Together, they discussed the importance of organoid research to develop new diagnostics, described use cases for digital twins in cancer therapeutics selection and aligned on the overlap in stem cell longevity care and cancer care. 👏 Huge thanks to the organizers Corinne Alston and Roger Royse , panelists, and entrepreneurs who are working tirelessly to transform cancer care. #CancerTech #DigitalDx #HealthTech #OncologyInnovation #VentureCapital #StartupEcosystem #CancerCare #Stanford #WomenInVC #HealthcareInnovation

👏 Always excited to read what Jonathan Norris, Managing Director at HSBC Innovation, writes... his HSBC Report released today is a must-read for anyone navigating the evolving healthcare landscape. 📉📈 The report's insights into 1H 2025 Healthcare Venture Trends are especially timely. While we saw a few standout mega rounds, the report doesn’t shy away from the tougher realities of a challenging financing market, particularly the decline from Q1 to Q2 across most sectors. 📊 From sector-specific investment shifts to active VC, corporate, and growth investor activity — plus valuations and exits — this report is a valuable snapshot of where the market stands and where it may be headed. 🔗 Check out the report here: https://lnkd.in/gxEYQvSg We highly recommend giving it a read — and thank you again, Jonathan, for sharing your expertise with the broader healthcare and innovation community. #HealthcareInnovation #VentureCapital #DigitalHealth #HealthcareInvestment #HSBCInnovation #JonathanNorris #HealthcareTrends #StartupFunding #DigitalDxVentures Michele Colucci, Esq. Erin Niehaus - CFP®, CEPA

🚨 Addressing a Public Health Crisis with Innovation Labcorp and DigitalDx Ventures portfolio company NOWDiagnostics | NOWDx have joined forces to expand access to rapid syphilis testing in response to rising infection rates across the U.S. Through this partnership, the First to Know® Syphilis Test—currently the only FDA-authorized OTC rapid test for syphilis—will be distributed at no cost to select LGBTQ+ clinics, HIV/AIDS providers, and safety-net health centers nationwide. With over 209,000 reported cases in 2023—the highest since 1950—early detection and accessibility are critical. This initiative puts game-changing diagnostics in the hands of frontline care providers serving the communities most at risk. At DigitalDx Ventures we’re inspired by startups like NOWDiagnostics | NOWDx tackling urgent public health challenges through scalable tech—and proud to support innovations that make a real-world impact. PRESS RELEASE: https://lnkd.in/g-fNqpzJ Robert Weigle Stephen Tang Todd Grice Michele Colucci, Esq. #HealthTech  #PublicHealth  #STIawareness  #Diagnostics  #ImpactInvesting  #VentureCapital  #Labcorp  #NOWDx  #InnovationForGood

Last week, DigitalDx Ventures Partner Melody Po joined a distinguished panel at the H7 BioCapital Life Science VC Showcase 2025 — a premier virtual gathering of top-tier investors, founders, and thought leaders in Life Sciences. Hosted by H7 BioCapital, this year's showcase featured two dynamic pitch tracks — Therapeutics and Medtech — spotlighting some of the most innovative early-stage startups in healthcare. In addition to these standout founder pitches, the event brought together leading voices to discuss critical topics shaping the future of biotech and health innovation. Melody was honored to speak on the panel "Scaling Healthcare Companies and Planning for Exit", alongside an esteemed group of investors, legal experts, and entrepreneurs. The panel tackled key challenges faced by growth-stage healthcare companies and offered actionable insights into exit strategies in today’s complex venture landscape. The panelists also judged the pitch competition. Panelists included: • Catherine Liyun Zhang - shareholder, Carlton Fields (Moderator) • Bill Reichert – General Partner, Pegasus Tech Ventures • Ephraim Lindenbaum – Managing Director, Advance Ventures • Nola E. Masterson Masterson – General Partner, Portfolia Femtech Fund • Melody Po – Partner, DigitalDx Ventures • Gary Goldman MD, DDS, MBA, MD, DDS – Founding Partner, Global Health Impact Network & Funds We're proud to see our DigitalDx Ventures team contributing to such important conversations driving the future of healthcare innovation. Congratulations to the H7 BioCapital team for hosting a high-impact event! #VentureCapital  #VentureCapitalNews #LifeSciences  #Biotech  #MedTech  #DigitalHealth  #HealthcareInnovation  #DigitalDxVentures

🚀 How are VCs actually using AI agents—and where do we draw the line? On June 13th at the SHIFT VC Annual Conference in New York City, Michele Colucci, Esq., Founder + Managing Partner at DigitalDx Ventures, joined a forward-looking panel exploring just that. 🧠 The conversation—VC x AI Agents—unpacked how AI is transforming investor workflows, from sourcing and diligence to portfolio operations and beyond. 🔥 Hot topics included: • Red flags in data rooms • Open-source vs proprietary IP • “Responsible AI” vs speed-to-market • What tasks investors are actually handing off to AI Michele was joined by: 💡 Ali Hussain, CEO + Founder, Tabs 💡 Michelle Dhansinghani Limón, Top Tier Capital Partners 🎤 Moderated by Azeezat Azeez,Ph.D, VC Unleashed | Stanford University #VentureCapital #VCNews #AI #AIAgents #SHIFTVC #DigitalDxVentures #Innovation #FutureOfWork

Playground is really changing the narrative in women's health...and we're excited to be part of the journey!

Last week, DigitalDx Ventures Founder + Managing Partner Michele Colucci, Esq. was proud to be part of #BareItAll — a powerful event focused on breaking stigmas and starting honest conversations around women’s intimate health and hormonal wellness. Hosted by Playground and Joylux, Inc., the event brought together a powerhouse group of advocates and founders, including: 🎤 Christina Aguilera, Vocal Artist and Co-Founder, Playground 🎬 Halle Berry, Actress and Co-Founder, Re-Spin 📰 Tamsen Fadal, Emmy Award-winning journalist, Author, and Menopause Advocate These conversations are not only long overdue — they’re essential. As investors in breakthrough health tech and women-led innovation, we at DigitalDx Ventures believe education, access, and open dialogue are the cornerstones of better health outcomes for all women. We applaud the visionary women leading the way: ✨ Catherine Magee, CEO, Playground ✨ Sandy Vukovic, Co-Founder & CPO, Playground ✨ Kathleen Jordan, MD, CMO, Midi Health ✨ Carli Sapir, Founding Partner, Amboy Street Ventures ✨ Colette Courtion, CEO, Joylux, Inc ✨ Laura Beres, VP, Ulta Beauty ✨ Michele Colucci, Esq., Founder + Managing Partner, DigitalDx Ventures ✨ Tamsen Fadal, Author & Advocate Together, we’re moving the conversation forward — and investing in a future where women’s wellness is prioritized, understood, and celebrated. #WomensHealth  #BareItAll  #ImpactInvesting  #WomenInVenture  #Menopause  #WomensWellness  #HelloPlayground  #Joylux  #VentureCapital  #HealthTech  #FemTech  #WomenInHealth

DigitalDx Ventures Founder + Managing Partner Michele Colucci, Esq. will be featured on a VC x AI Agents panel at the SHIFT VC Annual Conference in New York City on June 13th. The panel will delve into how VCs are leveraging AI agents to reshape workflows, supercharge diligence, and rethink human capital. From sourcing and market mapping to portfolio ops, what’s getting automated, what’s too risky, and where are the biggest opportunities? TOPICS: • Red flags in data rooms 📁 • Open-source vs proprietary IP 🤝 • “Responsible AI” vs speed-to-market ⚖️ • What tasks investors are actually handing over to AI agents 🤖 PANELISTS: Michele Colucci, Esq., Founder + Managing Partner DigitalDx Ventures Ali Hussain, CEO + Founder Tabs Michelle Dhansinghani Limón, Top Tier Capital Partners Moderator Azeezat Azeez,Ph.D, VC Unleashed, Stanford University REGISTER: https://lnkd.in/edeiy7RA #VentureCapital #VentureCapitalNews #VCNews #AI #AIAgents

DigitalDx Ventures portfolio company Biotia is proud to announce that its tool BIOTIA-DX Resistance, achieved the highest prediction accuracy in the 2025 CAMDA (Critical Assessment of Massive Data Analysis) Antimicrobial Resistance Challenge. Hosted as part of the ISMB 2025 conference, CAMDA brings together top researchers from around the world to benchmark advanced computational tools on real-world datasets. Biotia's submission outperformed all other participating methods in predicting Antimicrobial Resistance profiles from metagenomic data, demonstrating the clinical and research power of our proprietary platform. "This recognition at CAMDA highlights our commitment to innovation in combating antimicrobial resistance," said David Danko, Chief Technology Officer at Biotia. "BIOTIA-DX Resistance is part of our broader mission to deliver actionable insights through genomic analysis and help clinicians make better-informed treatment decisions." Biotia will present its results at ISMB 2025 in Liverpool this July. The CAMDA presentation will detail the methods and performance behind the BIOTIA-DX Resistance pipeline and its implications for the future of Antimicrobial Resistance surveillance and diagnostics. Congratulations to Biotia CEO Niamh B. O'Hara and the @Biotia Team! PRESS RELEASE: https://lnkd.in/g9Bx9wTc ISCB - International Society for Computational Biology #HealthTechNews #AI #Healthtechnology #CAMDA #AntimicrobialResistanceChallenge2025